Treatment of human colorectal cancer (CRC) cells with IL-6 leads to the activation of STAT3, which directly represses the expression of the tumor suppressive p53-regulated miR-34a gene via a conserved STAT3-binding site in its first intron. Here, IL6 is linked to colorectal carcinoma.